Press Releases

GI Dynamics Announces FDA Approval for EndoBarrier Pivotal Trial

Pivotal trial to focus on reduction of hemoglobin A1c for patients diagnosed with type 2 diabetes and obesity • Primary Endpoint        Reduction of HbA1c at 1 year • Planned Study Size                                           Stage I: 50 EndoBarrier / 17 control                                  ...

read more

EndoBarrier Meta-Analysis Published in Diabetes Care Journal

BOSTON and SYDNEY – 10 May 2018 — GI Dynamics® Inc. (ASX: GID), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce the meta-analysis, “Effects of the Duodenal-Jejunal Bypass Liner on Glycemic Control in Type 2 Diabetic...

read more

GI Dynamics Announces Close of Second Tranche of Placement – AUD ~$1m

BOSTON and SYDNEY — 8 March 2018 — GI Dynamics®, Inc. (ASX:GID), a medical device company that is developing EndoBarrier® is pleased to announce that it has today successfully completed the second tranche of the Placement (as detailed further in the 23 January 2018 announcement).  The closing of...

read more

GI Dynamics, Inc. Announces Results of Adjourned Special Meeting

BOSTON and SYDNEY — 28 February 2018 — GI Dynamics®, Inc. (ASX:GID), a medical device company that is developing EndoBarrier®, held an adjourned Special Meeting on Tuesday, 27 February 2018 at 3:00pm Eastern Standard Time (being Wednesday, 28 February 2018 at 7:00am Australian Eastern Daylight...

read more
Page 1 of 2012345...1020...Last »